| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7ddc4774cf5f8a0bda44a780d73c53d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-605 |
| filingDate |
2019-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aaaa024eec59427699acaa88023d52fc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_690cf824ad030eb757f4f434066c3408
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d02c9990cf09ee7e1451aee144a2dff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73a8d4cc16357235942e34e3fda3ffb9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ceba070752048340ff9a5b6d9aadd3d |
| publicationDate |
2019-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2019081777-A |
| titleOfInvention |
Insulin Secretory Peptide Derivative with Modified N-Terminal Charge |
| abstract |
The present invention provides an insulinotropic peptide derivative having a larger dissociation constant (Kd) for a GLP-1 receptor as compared to an insulinotropic peptide. The insulinotropic peptide derivative is characterized in that the positive charge at the N-terminus of the insulinotropic peptide is modified to a neutral charge or a net negative charge at neutral pH. The insulinotropic peptide derivative according to the present invention is a natural insulinotropic peptide while the dissociation from the GLP-1 receptor is rapidly promoted by the modification of the N-terminal charge as described above, and the stability in blood is maintained. It can be used very effectively for the treatment of type 2 diabetes, since it has an increased ability to secrete insulin and lower blood glucose levels as compared to [Selected figure] Figure 3 |
| priorityDate |
2013-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |